title: Opiorphin-dependent upregulation of CD73 (a key enzyme in the adenosine signaling pathway) in corporal smooth muscle cells exposed to hypoxic conditions and in corporal tissue in pre-priapic sickle cell mice.
abstract: The precise molecular mechanisms underlying priapism associated with sickle cell disease remain to be defined. However, there is increasing evidence that upregulated activity of the opiorphin and adenosine pathways in corporal tissue, resulting in heighted relaxation of smooth muscle, have an important role in development of priapism. A key enzyme in the adenosine pathway is CD73, an ecto-5'-nucleotidase (5'-ribonucleotide phosphohydrolase; EC 3.1.3.5) which catalyzes the conversion of adenosine mononucleotides to adenosine. In the present study we investigated how sickle cell disease and hypoxia regulate the interplay between opiorphin and CD73. In the corpora of sickle cell mice we observed significantly elevated expression of both the mouse opiorphin homolog mSmr3a (14-fold) and CD73 (2.2-fold) relative to non-sickle cell controls at a life stage before the exhibition of priapism. Sickle cell disease has a pronounced hypoxic component, therefore we determined if CD73 was also modulated in in vitro corporal smooth muscle (CSM) models of hypoxia. Hypoxia significantly increased CD73 protein and mRNA expression by 1.5-fold and 2-fold, respectively. We previously demonstrated that expression of another component of the adenosine signaling pathway, the adensosine 2B receptor, can be regulated by sialorphin (the rat opiorphin homolologue), and we demonstrate that sialorphin also regulates CD73 expression in a dose- and time-dependent fashion. Using siRNA to knockdown sialorphin mRNA expression in CSM cells in vitro, we demonstrate that the hypoxic upregulation of CD73 is dependent on the upregulation of sialorphin. Overall, our data provide further evidence to support a role for opiorphin in CSM in regulating the cellular response to hypoxia or sickle cell disease by activating smooth muscle relaxant pathways.
authors.affiliation: Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: S
authors.initials: S
authors.lastname: Fu
authors.affiliation: 1] Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA [2] Department of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: K P
authors.initials: KP
authors.lastname: Davies
mesh_terms: D015720:5'-Nucleotidase / Q000235:genetics*; D000241:Adenosine / Q000502:physiology*; D000755:Anemia, Sickle Cell / Q000150:complications / Q000235:genetics* / Q000378:metabolism*; D000818:Animals; D002478:Cells, Cultured; D058851:GPI-Linked Proteins / Q000235:genetics; D000860:Hypoxia / Q000503:physiopathology; D008297:Male; D051379:Mice; D009126:Muscle Relaxation / Q000187:drug effects; D009130:Muscle, Smooth / Q000378:metabolism*; D009842:Oligopeptides / Q000235:genetics*; D011317:Priapism / Q000209:etiology / Q000235:genetics*; D011498:Protein Precursors / Q000235:genetics / Q000502:physiology; D034741:RNA, Small Interfering / Q000494:pharmacology; D051381:Rats; D043704:Receptor, Adenosine A2B / Q000235:genetics; D012471:Salivary Proteins and Peptides / Q000235:genetics* / Q000502:physiology; D015398:Signal Transduction / Q000235:genetics*
chemical_list: D058851:GPI-Linked Proteins; D009842:Oligopeptides; D011498:Protein Precursors; D034741:RNA, Small Interfering; D043704:Receptor, Adenosine A2B; D012471:Salivary Proteins and Peptides; C066861:Smr3b protein, rat; C517879:glutaminyl-arginyl-phenylalanyl-seryl-arginine; D015720:5'-Nucleotidase; C548241:NT5E protein, human; D000241:Adenosine
references.citation: Neuroscience. 2011 Nov 24;196:25-34
references.pmid: 21925238
references.citation: J Urol. 2007 Jul;178(1):338-43
references.pmid: 17512016
references.citation: J Biol Chem. 1994 Feb 11;269(6):4355-9
references.pmid: 8308005
references.citation: FASEB J. 2014 Aug;28(8):3633-44
references.pmid: 24803544
references.citation: Science. 1992 Jul 17;257(5068):401-3
references.pmid: 1378650
references.citation: BJU Int. 2007 Feb;99(2):431-5
references.pmid: 17026587
references.citation: J Sex Med. 2010 Nov;7(11):3553-64
references.pmid: 19889148
references.citation: Curr Opin Hematol. 2013 May;20(3):215-21
references.pmid: 23549375
references.citation: Front Immunol. 2013 Jul 18;4:203
references.pmid: 23882269
references.citation: J Clin Invest. 2008 Apr;118(4):1491-501
references.pmid: 18340377
references.citation: FASEB J. 2014 Jan;28(1):76-84
references.pmid: 24076963
references.citation: Nat Med. 2008 Jan;14(1):45-54
references.pmid: 18066075
references.citation: Invest Ophthalmol Vis Sci. 2002 Sep;43(9):3037-44
references.pmid: 12202527
references.citation: FASEB J. 2014 Jun;28(6):2725-35
references.pmid: 24614760
references.citation: J Urol. 2003 Aug;170(2 Pt 2):S6-13; discussion S13-4
references.pmid: 12853766
references.citation: J Urol. 1992 Oct;148(4):1323-5
references.pmid: 1404667
references.citation: BJU Int. 2006 Aug;98(2):396-401
references.pmid: 16879685
references.citation: Am J Physiol Cell Physiol. 2009 Oct;297(4):C916-27
references.pmid: 19657052
references.citation: J Urol. 2008 Aug;180(2):760-6
references.pmid: 18554633
references.citation: J Clin Invest. 2002 Oct;110(7):993-1002
references.pmid: 12370277
references.citation: Pharmacol Rev. 2001 Dec;53(4):527-52
references.pmid: 11734617
references.citation: J Urol. 2003 Jul;170(1):298-301
references.pmid: 12796709
references.citation: Arch Intern Med. 1980 Nov;140(11):1434-7
references.pmid: 6159833
references.citation: J Sex Med. 2009 Mar;6 Suppl 3:292-301
references.pmid: 19267852
references.citation: J Sex Med. 2011 Aug;8(8):2172-80
references.pmid: 21595838
references.citation: Annu Rev Pharmacol Toxicol. 2001;41:775-87
references.pmid: 11264476